| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Children’s Hospital Oakland Research Institute, Oakland, CA 94609; and
Immunological Research Institute of Siena, Chiron Vaccines, Siena, Italy
Genome-derived neisserial Ag (GNA) 1870 is a meningococcal vaccine candidate that can be subdivided into three variants based on amino acid sequence variability. Variant group 1 accounts for 
60% of disease-producing group B isolates. The Ag went unrecognized until its discovery by genome mining because it is expressed in low copy number by most strains. To investigate the relationship between Ab binding to GNA1870 and complement-mediated protective functions, we prepared a panel of four murine IgG mAbs against rGNA1870 (variant 1) and evaluated their activity against nine genetically diverse encapsulated Neisseria meningitidis strains expressing subvariants of variant 1 GNA1870. Based on flow cytometry with live encapsulated bacteria, surface accessibility of the epitopes recognized by the mAbs appeared to be low in most strains. Yet mAb concentrations <1 to 5 µg/ml were sufficient to elicit bactericidal activity with human complement and/or activate C3b deposition on the bacterial surface. Certain combinations of mAbs were highly bactericidal against strains that were resistant to bactericidal activity of the respective individual mAbs. The mAbs conferred passive protection against bacteremia in infant rats challenged by strains resistant to bacteriolysis, and the protective activity paralleled the ability of the mAb to activate C3b deposition. Thus, despite low GNA1870 surface exposure, anti-GNA1870 variant 1 Abs are bactericidal and/or elicit C3b deposition and confer protection against bacteremia caused by encapsulated N. meningitidis strains expressing GNA1870 subvariant 1 proteins. The data support GNA1870 as a promising vaccine candidate for prevention of meningococcal group B disease caused by GNA1870 variant 1 strains.
This article has been cited by other articles:
|
|
 |
|
  P. T. Beernink and D. M. Granoff The modular architecture of meningococcal factor H-binding protein Microbiology, September 1, 2009; 155(9): 2873 - 2883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Gorringe, S. Taylor, C. Brookes, M. Matheson, M. Finney, M. Kerr, M. Hudson, J. Findlow, R. Borrow, N. Andrews, et al. Phase I Safety and Immunogenicity Study of a Candidate Meningococcal Disease Vaccine Based on Neisseria lactamica Outer Membrane Vesicles Clin. Vaccine Immunol., August 1, 2009; 16(8): 1113 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Plested, J. A. Welsch, and D. M. Granoff Ex Vivo Model of Meningococcal Bacteremia Using Human Blood for Measuring Vaccine-Induced Serum Passive Protective Activity Clin. Vaccine Immunol., June 1, 2009; 16(6): 785 - 791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cantini, D. Veggi, S. Dragonetti, S. Savino, M. Scarselli, G. Romagnoli, M. Pizza, L. Banci, and R. Rappuoli Solution Structure of the Factor H-binding Protein, a Survival Factor and Protective Antigen of Neisseria meningitidis J. Biol. Chem., April 3, 2009; 284(14): 9022 - 9026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Granoff, J. A. Welsch, and S. Ram Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera Infect. Immun., February 1, 2009; 77(2): 764 - 769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Koeberling, S. Giuntini, A. Seubert, and D. M. Granoff Meningococcal Outer Membrane Vesicle Vaccines Derived from Mutant Strains Engineered To Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2 Clin. Vaccine Immunol., February 1, 2009; 16(2): 156 - 162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Seib, D. Serruto, F. Oriente, I. Delany, J. Adu-Bobie, D. Veggi, B. Arico, R. Rappuoli, and M. Pizza Factor H-Binding Protein Is Important for Meningococcal Survival in Human Whole Blood and Serum and in the Presence of the Antimicrobial Peptide LL-37 Infect. Immun., January 1, 2009; 77(1): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Beernink, J. A. Welsch, M. Bar-Lev, O. Koeberling, M. Comanducci, and D. M. Granoff Fine Antigenic Specificity and Cooperative Bactericidal Activity of Monoclonal Antibodies Directed at the Meningococcal Vaccine Candidate Factor H-Binding Protein Infect. Immun., September 1, 2008; 76(9): 4232 - 4240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Beernink and D. M. Granoff Bactericidal Antibody Responses Induced by Meningococcal Recombinant Chimeric Factor H-Binding Protein Vaccines Infect. Immun., June 1, 2008; 76(6): 2568 - 2575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Welsch and D. Granoff Immunity to Neisseria meningitidis Group B in Adults despite Lack of Serum Bactericidal Antibody Clin. Vaccine Immunol., December 1, 2007; 14(12): 1596 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Boutriau, J. Poolman, R. Borrow, J. Findlow, J. D. Domingo, J. Puig-Barbera, J. M. Baldo, V. Planelles, A. Jubert, J. Colomer, et al. Immunogenicity and Safety of Three Doses of a Bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) Meningococcal Outer Membrane Vesicle Vaccine in Healthy Adolescents Clin. Vaccine Immunol., January 1, 2007; 14(1): 65 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Beernink, A. Leipus, and D. M. Granoff Rapid Genetic Grouping of Factor H-Binding Protein (Genome-Derived Neisserial Antigen 1870), a Promising Group B Meningococcal Vaccine Candidate. Clin. Vaccine Immunol., July 1, 2006; 13(7): 758 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Madico, J. A. Welsch, L. A. Lewis, A. McNaughton, D. H. Perlman, C. E. Costello, J. Ngampasutadol, U. Vogel, D. M. Granoff, and S. Ram The Meningococcal Vaccine Candidate GNA1870 Binds the Complement Regulatory Protein Factor H and Enhances Serum Resistance J. Immunol., July 1, 2006; 177(1): 501 - 510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Toropainen, L. Saarinen, G. Vidarsson, and H. Kayhty Protection by Meningococcal Outer Membrane Protein PorA-Specific Antibodies and a Serogroup B Capsular Polysaccharide-Specific Antibody in Complement-Sufficient and C6-Deficient Infant Rats. Infect. Immun., May 1, 2006; 74(5): 2803 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. J. Turner, A. G. Marietou, L. Johnston, K. K. L. Ho, A. J. Rogers, K. G. Wooldridge, and D. A. A. Ala'Aldeen Characterization of MspA, an Immunogenic Autotransporter Protein That Mediates Adhesion to Epithelial and Endothelial Cells in Neisseria meningitidis. Infect. Immun., May 1, 2006; 74(5): 2957 - 2964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cantini, S. Savino, M. Scarselli, V. Masignani, M. Pizza, G. Romagnoli, E. Swennen, D. Veggi, L. Banci, and R. Rappuoli Solution Structure of the Immunodominant Domain of Protective Antigen GNA1870 of Neisseria meningitidis J. Biol. Chem., March 17, 2006; 281(11): 7220 - 7227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Harrison Prospects for Vaccine Prevention of Meningococcal Infection Clin. Microbiol. Rev., January 1, 2006; 19(1): 142 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Giuliani, L. Santini, B. Brunelli, A. Biolchi, B. Arico, F. Di Marcello, E. Cartocci, M. Comanducci, V. Masignani, L. Lozzi, et al. The Region Comprising Amino Acids 100 to 255 of Neisseria meningitidis Lipoprotein GNA 1870 Elicits Bactericidal Antibodies Infect. Immun., February 1, 2005; 73(2): 1151 - 1160. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
